Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Authors_(Last_Name)

Ambari A.M., Setianto B., Santoso A., Radi B., Dwiputra B., Susilowati E., Tulrahmi F., Wind A., Cramer M.J.M., Doevendans P.

Author S Id

57189576921;57192893995;36905206100;6603494019;57195383994;57200092387;57210209635;57265425700;7102305152;7004918581;

Title

Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: The RamiRHeD trial protocol

Year

2021

Source Title

BMJ Open

Volume

Issue

Art No

e048016

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115217044&doi=10.1136%2fbmjopen-2020-048016&partnerID=40&md5=37438fc881ccc33516a8361ba43e3971

Affiliations

Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Central Military Hospital, Netherlands Heart Institute, Utrecht, Netherlands

Authors With Affiliations

Ambari, A.M., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Setianto, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Santoso, A., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Radi, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Dwiputra, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Susilowati, E., Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Tulrahmi, F., Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Wind, A., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Cramer, M.J.M., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Doevendans, P., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, Central Military Hospital, Netherlands Heart Institute, Utrecht, Netherlands

Abstract

Introduction Rheumatic heart disease (RHD) is a major burden in developing countries and accounts for 80% of all people living with the disease, where it causes most cardiovascular morbidity and mortality in children and young adults. Chronic inflammation and fibrosis of heart valve tissue due to chronic inflammation in RHD will cause calcification and thickening of the impacted heart valves, especially the mitral valve. This fibrogenesis is enhanced by the production of angiotensin II by increased transforming growth factor ? expression and later by the binding of interleukin-33, which is known to have antihypertrophic and antifibrotic effects, to soluble sST2. sST2 binding to this non-natural ligand worsens fibrosis. Therefore, we hypothesise that ACE inhibitors (ACEIs) would improve rheumatic mitral valve stenosis. Methods and analysis This is a single-centre, double-blind, placebo-controlled, randomised clinical trial with a pre-post test design. Patients with rheumatic mitral stenosis and valve dysfunction will be planned for cardiac valve replacement operation and will be given ramipril 5 mg or placebo for a minimum of 12 weeks before the surgery. The expression of ST2 in the mitral valve is considered to be representative of cardiac fibrosis. Mitral valve tissue will be stained by immunohistochemistry to ST2. Plasma ST2 will be measured by ELISA. This study is conducted in the Department of Cardiology and Vascular Medicine, Universitas Indonesia, National Cardiac Center Harapan Kita Hospital, Jakarta, Indonesia, starting on 27 June 2019. Ethics and dissemination The performance and dissemination of this study were approved by the ethics committee of National Cardiovascular Center Harapan Kita with ethical code LB.02.01/VII/286/KEP.009/2018. Trial registration number NCT03991910. ? 2021 BMJ Publishing Group. All rights reserved.

Author Keywords

cardiology; cardiothoracic surgery; valvular heart disease

Index Keywords

Publisher

BMJ Publishing Group

Issn

20446055

Isbn

Pubmed Id

34518254

Document Type

Article

Sjr Best Quartile

Sjr

1132

Sjr Rank

3624